Taysha Gene Therapies Inc (NAS:TSHA)
$ 2.06 -0.09 (-4.19%) Market Cap: 413.83 Mil Enterprise Value: 369.69 Mil PE Ratio: 0 PB Ratio: 7.09 GF Score: 31/100

Taysha Gene Therapies Inc at JMP Securities Life Sciences Conference Transcript

Jun 16, 2022 / 05:00PM GMT
Release Date Price: $2.87 (-4.65%)
Silvan Türkcan
JMP Securities LLC - Analyst

My name is Silvan Türkcan; I cover precision medicines here at JMP Securities. It's my pleasure to host Kamran Alam, CFO of Taysha; and Suyash Prasad, Chief Medical Officer of Taysha. Thank you very much for joining us today.

Kamran Alam
Taysha Gene Therapies, Inc. - CFO

Thanks very much. Appreciate it.

Suyash Prasad
Taysha Gene Therapies, Inc. - CMO & Head of Research and Development

Pleasure to be here.

Questions & Answers

Silvan Türkcan;Suyash Prasad
JMP Securities LLC - Analyst;Taysha Gene Therapies, Inc. - CMO

Thanks. So obviously, gene therapies have had a unique set of issues over the last, call it, 12 to 18 months apart from the general biotech market. Could you please tell us about what kind of company are you building in the gene therapy space to weather some of the challenges that other competitors may have had? And what's your focus, and how do you make it work?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot